NV-QUECTEL-WIRELESS
9.1.2023 07:16:19 CET | Business Wire | Press release
CES – Quectel Wireless Solutions, a global IoT solutions provider, is today demonstrating its smart module capabilities with compute-intensive and edge intelligence applications. Using Quectel’s high performance SG865W-WF smart module, the demonstration showcases how future use cases of industrial applications, digital signage, unattended retail, fleet management and healthcare can be enabled with edge intelligence and machine vision functionality.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230106005278/en/
Quectel continues to drive digital transformation with advanced smart module, edge intelligence and machine vision technologies at CES 2023 (Graphic: Business Wire)
The SG865W-WF is Quectel’s new generation of Android smart module with built-in octa-core high-performance Kryo 585 CPU, Adreno 650 GPU, Adreno 995 DPU, Adreno 665 VPU, Hexagon DSP, and Spectra 480 ISP. The module supports Wi-Fi 6, Bluetooth 5.1 and 2 × 2 Wi-Fi MIMO technology. A rich set of interfaces such as LCM, camera, touch panel, I2S, PCIe, UART, USB, I2C, SPI, etc. allow the module to serve a wide range of IoT applications including a state-of the-art visual inspection system currently deployed in Quectel’s own automated module production line.
Utilizing the Qualcomm QCS8250 system-on-chip, the Quectel SG865W-WF smart module and industrial equipment including a camera, lens and light, the machine vision solution uses edge computing to deliver the real-time analysis needed to identify defective samples including scratches, dirt, and abnormal surface printing on each module, screening out any defective modules during production. By deploying this solution, Quectel has realized industry-leading accuracy and high-speed defect detection - greatly improving the production efficiency and quality of our products.
“We are committed to driving digital transformation across all industry sectors through our broad IoT portfolio, working closely with our technology partner, Qualcomm,” commented Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “The visual inspection solution we have implemented in our own factories, is an excellent example of how we are not only creating the ground-breaking smart modules needed for advanced applications, but also using the technology in our own manufacturing to create a best-in-breed, industry leading defect detection system – helping us to greatly improve quality while saving production costs.”
The visual inspection solution is just one of a range of solutions that have used Quectel smart modules to enable high performance, edge computing and machine vision functionality. Customers looking to develop advanced machine vision and edge intelligence based solutions can work closely with Quectel’s experts to create customized solutions.
To learn more, visit the Quectel booth at CES 2023, North Hall, Booth #10862 where we will be demonstrating the Quectel machine vision solution with edge capabilities.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules, antennas and IoT connectivity. With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230106005278/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom